News
Yourlocation: Home > News > Chenodeoxycholic acid and ursodeoxycholic acid have been approved by the US Food and Drug Administration (FDA) for the treatment of cholelithiasis
Two cholic acid components (ursodeoxycholic acid and chenodeoxycholic acid) have been approved by the US Food and Drug Administration (FDA) for the treatment of cholelithiasis. These bile acids can reduce the production of cholesterol and reduce the incidence of hypertriglyceridemia, reduce the risk of coronary heart disease.
The toad steroid is present in the important medicinal herbs of the musk pills, and is a potent mediator with a positive inotropic drug derived from a herbal medicine that increases cardiac contractility and inhibits heart failure disinfected renin - aldosterone system.
Modern separation techniques such as gas phase and liquid chromatography combined with mass spectrometry techniques can help to clearly analyze the exact chemical composition of traditional Chinese medicine prescriptions.
So far, 70 nonvolatile components and 40 volatile components in the musk heart have been confirmed. In the subsequent study also found 22 prototype blood transfusion components and 8 metabolites. The application of these analytical techniques contributes to the establishment of the chemical fingerprints of musk pills. The technology is conducive to the control of the stability between the drug and the product batch, which provides an important technical guarantee for the clinical efficacy and safety of the traditional Chinese medicine compound preparation.
In addition, a variety of types of compounds, such as toad steroid, ginsenosides and cholic acids, have been found in the muscadain.
The above factors that reduce cholesterol, triglyceride blood levels and increase myocardial contractility may be one of the preparations for the heart protection function of muscadine. In the method of reducing the preparation of the compound preparation method, it is necessary to fully explain the important mechanism of the compound and the active compound need further study.

Address:A3 Building, Dongli Aviation Business District,No.8,Pingying Road, Dongli District, Tianjin, P.R.China, 300300 Tel:+86-022-58602231 Fax:+86-022-58602232 Email:nwsbio@163.com
Copyright © Tianjin NWS Biotechnology and Medicine Co. Ltd.

Reduce
Open